Meibomian gland dysfunction
Conditions
Interventions
Meibomian gland dysfunction group :None
Sponsors
Department of Ophthalmology and Visual Sciences (DOVS), Chinese University of Hong Kong
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.MGD patients: (1) >=18 years of age with no upper age limit; (2) Provide informed consent; (3) Newly diagnosed with MGD within the last twelve months; (4) Symptomatic dry eye ocular surface disease index (OSDI) = 13; (5) Mild to moderate (level 3-4) MGD on at least one eye; (6) Ethnic Chinese 2.Control Group: (1) >=18 years of age with no upper age limit; (2) Provide informed consent; (3) Symptomatic dry eye ocular surface disease index (OSDI) < 13; (4) Mild to moderate (level 0-2) MGD on both eyes; (5) Ethnic Chinese
Exclusion criteria
Exclusion criteria: MGD patients and the control group: (1) Contact lens wear 3 months before or during the study period; (2) Use of topical (including anti-glaucomatous, cyclosporin, antibiotics, steroid) or systemic medication known to affect (worsen or improve) MGD 3 months before or during the study period; (3) Major systemic (e.g. Sjogren’s syndrome), dermatologic (e.g. Rosacea) known to affect MGD or ocular conditions (including thyroid eye disease, recurrent conjunctivitis, ocular allergies); (4) Ocular procedures (excluding uncomplicated cataract operation) 3 months before and any ocular procedure during the study period; (5) Dermatological treatment [including chemical peeling, laser, intense pulsed light (IPL) or energy device in the periocular and facial region] 6 months before or during the study period; (6) Contraindications to IPL therapy (including recent sun-burn, photosensitivity, active or pigmented skin lesions, cancer, implants, tattoos, semi-permanent makeup in the periocular area; (7) Women who are pregnant, nursing, planning pregnancy, or of childbearing potential not using a reliable method of contraception; (8) Tear breakup time (TFBUT)>10 seconds in both eyes; (9) Presence of eyelid pathologies and malposition including eyelid swelling, dermatochalasis, entropion, ectropion, lash ptosis and lagophthalmos.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The ophthalmopathy status of the MGD patients and healthy subjects;The meibum metabolomics in local Hong Kong MGD patients; | — |
Secondary
| Measure | Time frame |
|---|---|
| The correlations of metabolites with meibomian gland and ocular surface parameter; | — |
Countries
China
Contacts
Public ContactCHU Wai Kit
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong
Outcome results
None listed